Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV
Shumway, David
Dynport Vaccine Company, LLC, Frederick, MD, United States
Search 14 grants from David Shumway
Search grants from Dynport Vaccine Company, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Support of Training of HIV Health Care Providers in the Republic of Botswana Unde
Storytelling for Empowerment
Middle Ear Development
Biomedical Research Support
Biomedical Research Support
Recently added grants:
Semi-Parametric Subgroup Analysis for Longitudinal Data with Applications to Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Study
Regulation of Bile Acid Metabolism and Signaling in Metabolic Diseases
Novel Pathways for Kidney Stone Formation
Functional evaluation of a new GWAS locus that links visceral adiposity and type 2 diabetes
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201500005I-1-27200003-1
Application #
9430351
Study Section
Project Start
2016-08-23
Project End
2017-04-30
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost
Institution
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Related projects
Comments
Be the first to comment on David Shumway's grant